文献速递呼吸道感染

产丁酸肠道菌F. prausnitzii可预防细菌性肺炎

Butyrate-producing gut bacterium Faecalibacterium prausnitzii protects against bacterial pneumonia.
PubMed 文献 · Eur Respir J · 2025-11-06

该研究通过小鼠实验和人群转化分析,评估产丁酸肠道共生菌F. prausnitzii与A. soehngenii对细菌性肺炎的保护作用。小鼠预处理F. prausnitzii(非A. soehngenii)可减轻肺炎克雷伯菌感染;社区获得性肺炎患者肠道Faecalibacterium水平降低,且较高水平与较好临床结局相关。

要点

  • F. prausnitzii预处理可保护小鼠抵抗肺炎克雷伯菌肺炎。
  • CAP患者肠道Faecalibacterium水平较匹配对照降低。
  • 较高肠道Faecalibacterium水平与CAP及危重症患者较好结局相关。

核心结论

  • 首次表明肠道共生菌F. prausnitzii对细菌性肺炎提供保护并具有转化潜力。

研究设计与样本

  • 小鼠实验:C57BL/6J小鼠经丁酸、F. prausnitzii或A. soehngenii预处理后鼻内感染肺炎克雷伯菌。
  • 人群转化分析:115例社区获得性肺炎(CAP)患者及独立验证队列,评估直肠Faecalibacterium水平与免疫反应及临床结局的关联。

主要发现

  • F. prausnitzii预处理(而非A. soehngenii)使小鼠细菌生长和播散减少、器官损伤减轻、炎症 dampened。
  • F. prausnitzii与丁酸预处理类似,降低肺部IL-6和CXCL1。
  • CAP患者肠道Faecalibacterium较匹配对照降低;较高水平者IL-6产生能力较低、炎症基因表达下调。
  • 较高肠道Faecalibacterium水平与CAP及危重症患者较好临床结局相关,控制潜在混杂因素后仍显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gut microbiota play a protective role against pneumonia in mice, probably by producing the immunomodulatory short-chain fatty acid butyrate. Yet, butyrate has limited potential for clinical use due to its challenging handling in practice. We performed mouse experiments and translational analyses to determine whether butyrate-producing gut commensals, Faecalibacterium prausnitzii and Anaerobutyricum soehngenii, could provide protection against bacterial pneumonia and serve as next-generation probiotics. METHODS: We pre-treated C57BL/6J mice with butyrate, F. prausnitzii (recently reclassified as F. duncaniae) or A. soehngenii, and subsequently infected them intranasally with Klebsiella pneumoniae. To assess the relevance in humans, we assessed associations between rectal levels of Faecalibacterium, immune responses and clinical outcomes in 115 patients with community-acquired pneumonia (CAP) and in a separate validation cohort. RESULTS: Pre-treatment with F. prausnitzii, but not A. soehngenii, protected mice against bacterial pneumonia, as reflected by reduced bacterial growth and dissemination, lessened organ damage, and dampened inflammation. Similar to butyrate pre-treatment, F. prausnitzii resulted in reduced pulmonary interleukin (IL)-6 and CXCL1. In humans, gut Faecalibacterium was decreased during CAP compared to matched controls. CAP patients with higher gut Faecalibacterium levels had lower IL-6-producing capacity and downregulated inflammatory gene expression. Higher intestinal Faecalibacterium levels were associated with better clinical outcomes in independent cohorts of CAP and critically ill patients, which remained significant when controlled for potential confounders. CONCLUSION: This is the first study showing that the gut commensal F. prausnitzii provides protection against bacterial pneumonia and has translational potential. This motivates future studies investigating the clinical potential of F. prausnitzii as a novel probiotic for pneumonia.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Kullberg, van Linge, de Vos, et al. Butyrate-producing gut bacterium Faecalibacterium prausnitzii protects against bacterial pneumonia. Eur Respir J. 2025. PMID: 40774806. doi:10.1183/13993003.02208-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。